CLOSED - Clinical Trial on Eczema (Atopic Dermatitis) in LA TBD

Description

Randomized double-blind Placebo controlled study of the efficacy and safety of CBP-201 in patients with moderate to severe Atopic Dermatitis / Eczema. The study duration is approximately 6 months and patients who respond to the drug will be able to chose to continue for up to one year. Patients will receive study drug every 2 weeks over the course of the treatment period which will be initially 16 weeks. CBP-201 is a recombinant monoclonal antibody that binds to IL-4 and IL-13 which are thought to play a role in the pathogenesis of Atopic Dermatitis / Eczama. Qualified Participants Must: • Be an adult between the ages of 18 and 75 years old with Atopic Dermatitis / Eczema for at least 1 year who have not had a complete response to topical treatments such as corticosteroid creams. • Females of child bearing potential need to be on effective birth control or abstain from heterosexual activities. • Participants should not be allergic to L-histidine, Trehalose, and Tween 80. Qualified Participants May Receive: A consultation from one of our healthcare providers and all study materials without charge. Regular visits and monitoring of blood samples as well as a supply of aquafor will also be provided without charge. No insurance is necessary to participate in this trial. Qualified participants will also receive compensation for their time and travel for all visits.

Space is limited, subject to availability. Criteria for qualification is subject to change at any time, and without notice.